13 August 2018

Tissue concentrations of amoxicillin in suckling piglets after single injection of Vetrimoxin® LA >

This study was conducted in order to evaluate the tissue concentration of amoxicillin in suckling piglet after injecting Vetrimoxin® LA

9 June 2018

Compatibility of Coglapest® and Coglapix® vaccines in pigs >

This study was conducted in order to test the compatibility of Coglapix® and Coglapest® vaccines, when the latter was reconstituted in Coglapix®.

21 May 2018

Comparison of vaccination with Coglapix® and targeted medication in the prevention of pleuropneumonia in pigs >

Antibiotics are frequently used for the mass repeated medication in growing and finishing phase to control pleuropneumonia. Current trend in pig farming is to reduce the overall use of antibiotics, particularly in the oral forms. The aim of this study was to evaluate the impact of vaccination on health and economic balance in comparison with the targeted medication against A.p.

7 May 2017

Clinical efficiency of Vetrimoxin® LA in the control of early mortality in suckling piglets >

Prophylactic use of efficient antibiotics can reduce the incidence of the disease and decrease the losses due to mortality or crushing of weak, sick piglets. The aim of this study was to evaluate the efficacy of prophylactic treatment with Vetrimoxin® LA (amoxicillin inj., Ceva) in the farm with endemic S. suis infections in suckling piglets.

27 April 2017

Efficacy of Coglapix® and Hyogen® vaccines in the Prevention of Pleuropneumonia and Enzootic Pneumonia >

The aim of this study was to compare the efficacy of Coglapix® - A.p toxoid vaccine (Ceva) and Hyogen® - M. hyo vaccine (Ceva) with competitor vaccines in the farm with the history of enzootic disease caused by A.p and M. hyo.

20 April 2017

Determination of minimal inhibition concentrations of major antibiotics for Streptococcus suis >

The aim of this study was to compare the susceptibility of Streptococcus suis to amoxicillin (AMX) and other frequently used antibiotics in swine, namely ceftiofur (CEF) and marbofloxacin (MAR).

13 April 2017

Hyogen® with ImuvantTM - Superior Protection Against Mycoplasma hyopneumoniae infection >

- Single injection provides early and long lasting protection - Broad stimulation of the immune system with ImuvantTM - Trials demonstrate superior protection versus competitors - Expertise of the Ceva Lung Program

6 April 2017

VETRIMOXIN® LA - Technical profile >

Vetrimoxin® LA is the leading product in the Ceva anti-infective range. Within the group of historical antibiotics, the product has an extensive experience in the market as leader in its segment being a classical molecule in the daily work of veterinarians and farmers and ranking as a top choice molecule for use in the animal health field.